Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Clostridium difficile toxin (C. difficile) is a spore-forming, gram-positive, anaerobic bacillus known for producing two significant exotoxins, namely toxin A and toxin B. The detection of C. difficile toxin A is crucial in diagnosing infections, particularly in patients who are undergoing antibiotic treatment and exhibit symptoms of antibiotic-associated diarrhea. This bacterium is notorious for causing severe gastrointestinal conditions, including pseudomembranous colitis, toxic megacolon, perforations of the colon, and even sepsis, which can be life-threatening. The testing process involves obtaining a fecal specimen from the patient, which is then analyzed using a test kit designed for rapid chromatographic immunoassay. This immunoassay method allows for the quick detection of the C. difficile toxin A in the stool sample. The test kit employs a series of reagents that specifically target the C. difficile antigen. The presence of the toxin is indicated by a color change on the test strip or other testing platform, where a test line or dot will change color if the toxin is present, alongside a second control line or dot that confirms the test's validity. This method provides a rapid and effective means of diagnosing C. difficile infections, facilitating timely treatment and management of the condition.
© Copyright 2026 Coding Ahead. All rights reserved.
The procedure for detecting Clostridium difficile toxin A is indicated for patients who are suspected of having an infection due to C. difficile, particularly those who are currently on antibiotic therapy and present with symptoms of antibiotic-associated diarrhea. The following conditions warrant the use of this test:
The procedure for detecting Clostridium difficile toxin A involves several key steps that ensure accurate results. First, a fecal specimen is collected from the patient, which is essential for the subsequent testing process. This specimen must be handled with care to prevent contamination and ensure the integrity of the sample. Next, the fecal sample is introduced into a test kit specifically designed for rapid chromatographic immunoassay. This kit contains a series of reagents that react with the C. difficile antigen present in the stool. The test is performed by following the manufacturer's instructions, which typically involve adding the fecal sample to a designated area on the test strip. As the sample interacts with the reagents, a chromatographic reaction occurs, allowing for the detection of the toxin. The results are visually observed, with a color change indicating the presence of C. difficile toxin A. A test line or dot will change color if the toxin is present, while a control line or dot confirms that the test has been conducted correctly. This rapid testing method provides timely results, enabling healthcare providers to make informed decisions regarding patient management.
After the procedure, it is important to interpret the results of the C. difficile toxin A test accurately. If the test indicates the presence of the toxin, appropriate clinical management should be initiated, which may include starting or adjusting antibiotic therapy based on the patient's condition. In cases where the test is negative but clinical suspicion remains high, further diagnostic evaluation may be warranted. Patients should be monitored for any signs of complications associated with C. difficile infection, such as worsening diarrhea, abdominal pain, or signs of dehydration. Additionally, infection control measures should be implemented to prevent the spread of C. difficile, particularly in healthcare settings. Follow-up care may involve repeat testing or additional diagnostic procedures if symptoms persist or worsen.
| Short Descr | CLOSTRIDIUM TOXIN A W/OPTIC | Medium Descr | IAADIADOO CLOSTRIDIUM DIFFICILE TOXIN A | Long Descr | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Clostridium difficile toxin A | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 3 | CCS Clinical Classification | 206 - Microscopic examination (bacterial smear, culture, toxicology) |
| 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2022-01-01 | Changed | First appearance of change in codebook. |
| 2021-01-01 | Changed | First appearance of change in CPT® Code Set. |
| 2020-10-06 | Changed | Code description changed. |
| 2002-01-01 | Added | First appearance in code book in 2002. |
Get instant expert-level medical coding assistance.